Wir sind mit live! Mehr erfahren

Spero Therapeutics

SPRO

Börsenwert 64,1 Mio. $

1,10 USD

-0,03

2,65 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

1 Tag

-2,65 %

5 Tage

-8,33 %

1 Monat

-0,9 %

3 Monate

-29,94 %

6 Monate

-58,96 %

Seit Jahresbeginn

-53,19 %

1 Jahr

-53,19 %

5 Jahre

-93,49 %

10 Jahre

-90,43 %

Profil: Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Mitarbeiter: 25

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 18,2 %

Neutral 81,8 %

Negativ 0 %

Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, Spero's President and Chief Executive Officer, will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference to be held in New York City, on October 20th, 2026. Spero's leadership team will also be available for one-on-one meetings at the conference.

Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

Russian plague outbreak could boost these under-the-radar pharma stocks

Global biosecurity alarms are flashing after an incident at an anti-plague research facility in Siberia sparked a severe public health response. Following the fatal lab exposure of a researcher in Irkutsk region to Yersinia pestis – the bacterium causing pneumonic plague – Russian officials placed several regional hospitals under quarantine and isolated nearly 200 contacts.

Russian plague outbreak could boost these under-the-radar pharma stocks

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero's Board of Directors approved grants, made on October 1, 2026, of an aggregate of 233,000 restricted stock unit awards (RSUs) and 323,000 stock options to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The stock options and RSUs are being granted as an inducement material to Spero's new employees in accordance with Nasdaq Listing Rule 5635(c)(4).

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero's Board of Directors approved a grant, made on September 1, 2026, of an aggregate of 102,000 restricted stock unit awards (RSUs) and 67,600 stock options to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan).

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, President and Chief Executive Officer, will present at the H.C.

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript

Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript

Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript

Spero Therapeutics Q2 Earnings Call Highlights

Spero Therapeutics NASDAQ: SPRO used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for SP001, an antibody candidate the company plans to develop initially for IgG4-related disease.

Spero Therapeutics Q2 Earnings Call Highlights

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that on July 22, 2026, the Compensation Committee of Spero's Board of Directors approved a grant, to be made on August 3rd, of an aggregate of 324,622 stock options and 162,311 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan).

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that announced that it will report its financial results for the second quarter ended June 30, 2026 on Wednesday, August 12, 2026, after market close.

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt